# AnaptysBio, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/AnaptysBio, Inc). ## Overview AnaptysBio, Inc. is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its internal pipeline includes rosnilimab for rheumatoid arthritis and ulcerative colitis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for additional immune-mediated indications. The company also monetizes discoveries made through collaborations, including Jemperli (dostarlimab) with GSK and imsidolimab with Vanda Pharmaceuticals. As a result, AnaptysBio combines early-stage drug development with collaboration-based revenue from milestones, royalties, and license services rather than product sales. ## Products & services • Rosnilimab, a selective pathogenic T cell depleter • ANB033, a CD122 antagonist in clinical development • ANB101, a BDCA2 modulator in early trials • Jemperli (dostarlimab) collaboration with GSK • Imsidolimab license and transition services with Vanda • Milestone and royalty revenue from partnered antibodies - **Clinical-stage pipeline therapeutics** (0%) — Internally discovered antibody programs advancing through Phase 1 and Phase 2 trials for autoimmune and inflammatory diseases. - **Collaboration revenue** (100%) — Milestone, royalty, and research funding revenue from partnered programs such as GSK and Vanda. - **License and transition services** (0%) — Services tied to out-licensed assets and collaboration transition activities, especially under the Vanda agreement. - Rosnilimab for autoimmune and inflammatory diseases - ANB033 for celiac disease and eosinophilic esophagitis - ANB101 for immune-mediated disease targets - Jemperli (dostarlimab) collaboration with GSK - Imsidolimab exclusive license to Vanda - Milestone payments, royalties, and license revenue - Research and development of immunology antibody therapeutics ## Customers AnaptysBio does not sell commercial products directly to patients; its current revenue comes primarily from pharmaceutical collaboration partners. GSK is a key collaborator for Jemperli, and Vanda is a licensee for imsidolimab, making large biopharma partners the main paying counterparties. For future marketed products, the company’s end-market customers would be physicians, hospitals, and third-party payors that influence adoption and reimbursement in autoimmune and inflammatory diseases. The company also depends on clinical investigators, contract research organizations, and manufacturing vendors to advance its programs, even though these are not revenue customers. - **Pharmaceutical collaboration partners** (primary) — Large biopharma partners such as GSK and Vanda that pay upfront fees, milestones, royalties, and service revenue for licensed antibody assets. - **Healthcare providers** (secondary) — Physicians and treatment centers would prescribe any approved autoimmune or inflammatory disease therapies developed from the pipeline. - **Third-party payors** (secondary) — Commercial insurers and government programs that determine reimbursement and therefore the commercial viability of future products. - **Clinical research ecosystem** (secondary) — CROs, trial sites, and manufacturing vendors that support development and supply for the company’s clinical programs. - GSK pays milestones and royalties tied to Jemperli development and sales - Vanda pays upfront, supply, and potential milestone/royalty consideration - Future buyers would be healthcare providers prescribing approved therapies - Third-party payors matter because reimbursement drives uptake of biologics - Clinical trial sites and CROs support development but are not customers - Regulators indirectly shape demand by determining approval and labeling ## Geography AnaptysBio is headquartered in San Diego, California and operates primarily from the United States. Its business is global in the sense that collaboration agreements and future commercialization can extend into foreign markets, but the company’s disclosed operating footprint is centered in the U.S. The Vanda agreement explicitly includes potential regulatory and commercial milestones in both the U.S. and EU, showing that future value creation depends on multi-region approvals. The company also notes that its facilities are in a seismically active and wildfire-prone region, which creates operational concentration risk. - **United States** (100%) — Headquarters and primary operations are in San Diego, California; country-level revenue disclosure not provided. - Headquartered in San Diego, California - Core research and corporate operations are U.S.-based - Future commercialization may extend to Europe and other markets - Collaboration economics include U.S. and EU regulatory milestones - Single-site concentration increases disaster recovery risk - No country-level revenue disclosure was provided in the excerpts ## Strategy AnaptysBio’s strategy is to advance its internal immunology pipeline while monetizing selected discoveries through partnerships and licensing. The company is prioritizing clinical development of rosnilimab, ANB033, and ANB101 to generate proof-of-concept data in autoimmune and inflammatory diseases. At the same time, it seeks non-dilutive value creation through collaboration revenue, royalties, and license transactions such as the Vanda agreement. This dual model helps fund development, but it also means long-term value depends on clinical success, partner execution, and regulatory approvals. - **Advance rosnilimab clinical development** (short-term) — Rosnilimab is the lead internal program and the main driver of future standalone value creation. - **Expand proof-of-concept for ANB033 and ANB101** (medium-term) — Additional pipeline assets diversify scientific risk and broaden the company’s immunology franchise. - **Monetize partnered assets through royalties and milestones** (medium-term) — Collaboration economics provide funding and reduce dependence on equity financing. - Advance rosnilimab through later-stage autoimmune disease trials - Progress ANB033 and ANB101 to expand the pipeline beyond the lead asset - Monetize discovered antibodies through out-licensing and partnerships - Capture milestone and royalty economics from partnered assets - Use collaboration revenue to support R&D without relying on product sales - Build value through differentiated immunology mechanisms ## Risks The company faces the core biotechnology risk that its product candidates may fail in clinical development or be delayed, which would reduce the likelihood of future commercialization. Safety findings, weak efficacy, or unfavorable trial results could impair regulatory approval and market acceptance, especially because the company’s pipeline is still early stage. AnaptysBio also depends on collaborators such as GSK and Vanda to execute development and commercialization, so partner decisions and timelines can materially affect revenue. In addition, the company is exposed to operational concentration risk because its facilities are in San Diego, a region subject to earthquakes, wildfires, and power disruptions, and it relies on a geographically concentrated supply chain. - **Clinical development failure** [critical] — The company’s value depends on unproven pipeline assets advancing successfully through trials. - **Safety or tolerability issues in trials** [high] — Adverse events could reduce the chance of regulatory approval and commercial acceptance. - **Regulatory approval delays** [high] — Biologics cannot generate product revenue until approvals are obtained in the U.S. and abroad. - **Partner dependence** [high] — Milestones and royalties rely on collaborators’ development and commercialization performance. - **Natural disaster and site concentration** [medium] — San Diego operations face earthquake, wildfire, and power outage risk, with limited recovery redundancy. - Clinical trial failure or delay could eliminate or postpone future product value - Adverse safety data could block approval or limit physician adoption - Regulatory risk is high because approvals are required before commercialization - Partner execution risk affects milestone, royalty, and license revenue timing - Reimbursement and pricing pressure could limit uptake of approved biologics - San Diego facility concentration creates earthquake and wildfire exposure - Supply chain concentration can disrupt manufacturing and trial operations ## Accounting AnaptysBio’s reported revenue is driven by collaboration accounting rather than product sales, so the timing of milestone recognition and royalty accruals is a key analytical issue. Revenue can be lumpy because upfront fees are amortized over time, while milestone payments are recognized only when the underlying event occurs and royalties depend on partner sales. The company also has a sale of future royalties arrangement, which creates non-cash interest expense based on estimated future royalty streams and the effective interest method. Because it is a clinical-stage company, estimates around R&D accruals, stock-based compensation, and the valuation of investments and contingent consideration can materially affect quarterly results. - **Collaboration revenue recognition** — Can materially change reported revenue timing - **Sale of future royalties accounting** — Affects operating results and financing-related expense - **Clinical trial accruals** — Can cause period-to-period expense adjustments - **Stock-based compensation** — Raises non-cash G&A and R&D expense - Collaboration revenue depends on milestone timing and contract terms - Royalty revenue is tied to partner sales and can be volatile - Upfront license payments are typically recognized over the service period - Sale of future royalties creates non-cash interest expense - Clinical trial accruals require judgment on vendor invoices and services received - Stock-based compensation is a meaningful operating expense for a biotech company - Cash runway assumptions affect going-concern style liquidity analysis --- *Last updated: 2026-08-11T04:46:17.968844+00:00*